Görüşler arşivi

Hanpars’ın 2025 boyunca yayımladığı ilaç pazarı, tedarik ve regülasyon üzerine yazılar. Güncel bir tavsiye olarak değil, bağlam olarak özgün tarihleriyle burada tutulmaktadır.

Bir ihtiyacı görüşün
Bu yazılardaki rakamlar, öngörüler ve regülasyon atıfları yazıldıkları dönemi yansıtır ve güncellenmemiştir. Dayanmadan önce güncel kaynakları kontrol edin. Güncel başlıklar için Bugün ilaç haberleri sayfasına bakın.

20 arşiv yazısı

Key Trends in China's API Market for 2025-2026

China's API sector grows with focus on sustainability, complex molecules, and regulatory alignment...

API Trends

Key Trends Shaping China's Finished Dosage Formulation Market in 2025-2026

China's FDF sector evolves rapidly with a shift toward high-value, complex formulations amid steady market growth and policy support...

Market Trends

Leading API Manufacturers in China: Profiles and Innovations

Profiling top Chinese API producers like Zhejiang Huahai, CSPC Pharma, and their cutting-edge advancements...

Manufacturer Spotlight

Chinese Finished Dosage Formulations Going Global: Export Growth and International Impact

Chinese FDF manufacturers are expanding exports, gaining global share through quality improvements and partnerships...

Global Expansion

Global Impact of Chinese API Exports and Supply Chain Dynamics

Chinese APIs power 30-40% of global generics, with exports rising amid quality improvements...

Global Expansion

China as an Innovator in Finished Dosage Formulations: From Generics to Cutting-Edge Therapies

Chinese firms are driving FDF innovation in biosimilars, complex generics, and novel deliveries...

Innovation & Technology

Regulatory Changes Impacting China's API Sector

NMPA reforms align China's API industry with global standards, boosting quality and exports...

Regulatory Updates

Sustainability Initiatives in Chinese API Production

Chinese API makers adopt green chemistry and waste reduction amid environmental pressures...

Innovation & Technology

2030 Vision: The Future of China's API Industry

As we look toward 2030, China's Active Pharmaceutical Ingredient (API) industry stands at an inflection point, with transformative forces reshaping its trajecto…

Market Analysis

Cooperation & Competition: China's API Industry on the World Stage

The global Active Pharmaceutical Ingredient (API) landscape is characterized by a complex interplay of cooperation and competition, with China occupying a centr…

Market Analysis

Digital Transformation: How AI is Revolutionizing API Development in China

China's Active Pharmaceutical Ingredient (API) industry is experiencing a profound digital transformation, with artificial intelligence (AI) and advanced analyt…

Innovation & Technology

Sustainable Synthesis: Green Chemistry Initiatives in China's API Industry

China's Active Pharmaceutical Ingredient (API) industry is undergoing a significant transformation toward sustainability, with green chemistry initiatives gaini…

Innovation & Technology

Biological Revolution: China's Emerging Leadership in Biologic APIs

China's biopharmaceutical sector is undergoing a remarkable transformation, with rapid advances in biological Active Pharmaceutical Ingredients (APIs) positioni…

Innovation & Technology

Disease Demographics: How China's Health Challenges Drive API Innovation

China's evolving disease burden is creating a powerful domestic driver for pharmaceutical innovation, particularly in the Active Pharmaceutical Ingredients (API…

Therapeutic Focus

The $1.92 Billion Opportunity: How China's API Manufacturers Are Capitalizing on Patent Expirations

The pharmaceutical industry is approaching a significant patent cliff, with blockbuster drugs worth over $1.92 billion facing patent expiration between 2024 and…

Market Analysis

The Dragon's Grip: How China Dominates Global Pharmaceutical Supply Chains

China's dominance in global pharmaceutical supply chains has reached unprecedented levels, creating both opportunities and challenges for the global healthcare …

Supply Chain

Capital Influx: Major Investments Reshaping China's API Manufacturing Capabilities

The Chinese API manufacturing sector is experiencing an unprecedented wave of capital investment, fundamentally transforming the industry's capabilities and glo…

Market Analysis

Beyond Generics: China's Strategic Pivot to High-Value API Production

The landscape of China's Active Pharmaceutical Ingredient (API) industry is undergoing a profound transformation. Once primarily known as the world's factory fo…

Innovation & Technology

Regulatory Evolution: How China's New API Policies Are Reshaping the Global Pharmaceutical Landscape

China's regulatory framework for Active Pharmaceutical Ingredients (APIs) has undergone a profound transformation in recent years, culminating in comprehensive …

Regulatory Updates

China's API Market in 2025: A $15.97 Billion Industry Poised for Growth

China's Active Pharmaceutical Ingredient (API) market stands as a cornerstone of drug manufacturing worldwide. As we navigate through 2025, this critical sector…

Market Analysis

Ürünü ve pazarı bize söyleyin. Bir sonraki adımı biz söyleyelim.

Molekülü veya hammaddeyi, spesifikasyonu ve hedef ülkeyi gönderin. Tahran’dan sorularımız, belge taleplerimiz ve bir sonraki adımla size dönüş yaparız.

Tedarik talebi hazırlayınRuhsatlandırma veya CDMO desteğini görüşün
Telefon+98 21 8888 3325 · çalışma saatleri 09:00–17:00, Tahran saati
OfisHaniya Parsan Darou, 3. kat, No: 326, Zafar Sokağı, Africa Bulvarı, Tahran 1968734974, İran
E-postacontact@hanpars.com